Immunotherapy Promising for Slowing Progression of ALS
A new immunotherapy appears to be well tolerated and possibly of benefit in patients with amyotrophic lateral sclerosis.
A new immunotherapy appears to be well tolerated and possibly of benefit in patients with amyotrophic lateral sclerosis.
There is a linear correlation for physical activity with amyotrophic lateral sclerosis.
Investigators sought to identify genetic factors that may contribute to the risk for neurodegenerative diseases, such as amyotrophic lateral sclerosis and frontotemporal dementia.
Investigators assessed patients with sporadic ALS to determine the relationship between somatosensory cortex excitability and survival prognosis.
Researchers found that for men with any occupational exposure to diesel exhaust, the odds ratio for amyotrophic lateral sclerosis increased with increasing lag periods.
Pseudobulbar affect is characterized by episodes of inappropriate laughing or crying, and may be associated with increased anxiety and depression, as well as lower mental health status.
Patients who received 100 mg/day riluzole spent significantly more time in stage 4 than patients who were randomly assigned to placebo.
Further research is warranted to clarify the role played by insulin resistance in the pathogenesis of amyotrophic lateral sclerosis.
The prevalence of ALS in the United States has been steady.
Due to the rarity of rapidly progressive SOD1 ALS, this study had a small sample size and may be limited in power.